Revisiting hypophosphatemic rickets/osteomalacia.
Bandgar T, Shah N.
Best Pract Res Clin Endocrinol Metab. 2024 Mar;38(2):101859. doi: 10.1016/j.beem.2024.101859. Epub 2024 Jan 6.
The pathophysiology of hypophosphatemia.
Ito N, Hidaka N, Kato H.
Best Pract Res Clin Endocrinol Metab. 2024 Mar;38(2):101851. doi: 10.1016/j.beem.2023.101851. Epub 2023 Nov 30.
Hypophosphatemia: A Practical Guide to Evaluation and Management.
Tebben PJ.
Endocr Pract. 2022 Oct;28(10):1091-1099. doi: 10.1016/j.eprac.2022.07.005. Epub 2022 Aug 6.
Osteomalacia Is Not a Single Disease.
Cianferotti L.
Int J Mol Sci. 2022 Nov 28;23(23):14896. doi: 10.3390/ijms232314896.
Hypophosphatemic rickets.
Baroncelli GI, Toschi B, Bertelloni S.
Curr Opin Endocrinol Diabetes Obes. 2012 Dec;19(6):460-7. doi: 10.1097/MED.0b013e328358be97.
[Osteomalacia].
Rosa J.
Vnitr Lek. 2023 Summer;69(4):254-260. doi: 10.36290/vnl.2023.048.
Uncovering genetic causes of hypophosphatemia.
Puente-Ruiz N, Docio P, Unzueta MTG, Lavín BA, Maiztegi A, Vega AI, Piedra M, Riancho-Zarrabeitia L, Mateos F, Gonzalez-Lamuño D, Valero C, Riancho JA.
J Intern Med. 2023 Jun;293(6):753-762. doi: 10.1111/joim.13635. Epub 2023 Apr 16.
Osteomalacia.
Francis RM, Selby PL.
Baillieres Clin Endocrinol Metab. 1997 Apr;11(1):145-63. doi: 10.1016/s0950-351x(97)80569-1.
Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial.
Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, Simmons JH, Padidela R, Namba N, Cheong HI, Pitukcheewanont P, Sochett E, Högler W, Muroya K, Tanaka H, Gottesman GS, Biggin A, Perwad F, Mao M, Chen CY, Skrinar A, San Martin J, Portale AA.
Lancet. 2019 Jun 15;393(10189):2416-2427. doi: 10.1016/S0140-6736(19)30654-3. Epub 2019 May 16.
Hypophosphatemia and growth.
Santos F, Fuente R, Mejia N, Mantecon L, Gil-Peña H, Ordoñez FA.
Pediatr Nephrol. 2013 Apr;28(4):595-603. doi: 10.1007/s00467-012-2364-9. Epub 2012 Nov 22.
